216 related articles for article (PubMed ID: 21239698)
41. High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia.
Sanz MA; Martínez J; Borrego D; Martín-Aragonés G; Lorenzo I; Sanz G; Sayas MJ; Jarque I; Pastor E; Rafecas J
Semin Oncol; 1987 Jun; 14(2 Suppl 1):18-20. PubMed ID: 3589692
[No Abstract] [Full Text] [Related]
42. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients.
Lejeune C; Tubiana N; Gastaut JA; Maraninchi D; Richard B; Launay MC; Sainty D; Sebahoun G; Carcassonne Y
Eur J Haematol; 1990 Apr; 44(4):240-3. PubMed ID: 2344886
[TBL] [Abstract][Full Text] [Related]
43. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.
Solary E; Caillot D; Chauffert B; Casasnovas RO; Dumas M; Maynadie M; Guy H
J Clin Oncol; 1992 Nov; 10(11):1730-6. PubMed ID: 1357108
[TBL] [Abstract][Full Text] [Related]
44. A phase I trial of flavopiridol in relapsed multiple myeloma.
Hofmeister CC; Poi M; Bowers MA; Zhao W; Phelps MA; Benson DM; Kraut EH; Farag S; Efebera YA; Sexton J; Lin TS; Grever M; Byrd JC
Cancer Chemother Pharmacol; 2014 Feb; 73(2):249-57. PubMed ID: 24241210
[TBL] [Abstract][Full Text] [Related]
45. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
46. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
47. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia.
Kantarjian HM; Walters RL; Keating MJ; Estey EH; O'Brien S; Schachner J; McCredie KB; Freireich EJ
Cancer; 1990 Jan; 65(1):5-8. PubMed ID: 2293869
[TBL] [Abstract][Full Text] [Related]
48. A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.
Dickson MA; Rathkopf DE; Carvajal RD; Grant S; Roberts JD; Reid JM; Ames MM; McGovern RM; Lefkowitz RA; Gonen M; Cane LM; Dials HJ; Schwartz GK
Invest New Drugs; 2011 Oct; 29(5):1004-12. PubMed ID: 20461440
[TBL] [Abstract][Full Text] [Related]
49. High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias.
Hiddemann W; Büchner T; Essink M; Koch O; Stenzinger W; van de Loo J
Onkologie; 1988 Feb; 11(1):10-2. PubMed ID: 3283619
[TBL] [Abstract][Full Text] [Related]
50. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.
Gill H; Yim R; Pang HH; Lee P; Chan TSY; Hwang YY; Leung GMK; Ip HW; Leung RYY; Yip SF; Kho B; Lee HKK; Mak V; Chan CC; Lau JSM; Lau CK; Lin SY; Wong RSM; Li W; Ma ESK; Li J; Panagiotou G; Sim JPY; Lie AKW; Kwong YL
Cancer Med; 2020 May; 9(10):3371-3382. PubMed ID: 32187883
[TBL] [Abstract][Full Text] [Related]
51. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Kern W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1998 Jul; 12(7):1049-55. PubMed ID: 9665189
[TBL] [Abstract][Full Text] [Related]
52. Mitoxantrone and intermediate-dose cytosine arabinoside for poor-risk acute leukemias: response to treatment and factors influencing outcome.
Sierra J; Grañena A; Bosch F; Carreras E; Martí JM; Urbano-Ispizua A; Rovira M; Rozman C
Hematol Oncol; 1992; 10(6):301-9. PubMed ID: 1296931
[TBL] [Abstract][Full Text] [Related]
53. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.
Karanes C; Kopecky KJ; Head DR; Grever MR; Hynes HE; Kraut EH; Vial RH; Lichtin A; Nand S; Samlowski WE; Appelbaum FR
Leuk Res; 1999 Sep; 23(9):787-94. PubMed ID: 10475617
[TBL] [Abstract][Full Text] [Related]
54. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
55. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
56. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
Paciucci PA; Cuttner J; Holland JF
Semin Oncol; 1984 Sep; 11(3 Suppl 1):36-40. PubMed ID: 6385264
[TBL] [Abstract][Full Text] [Related]
57. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
Koc Y; Oyan B; Kars A; Tekuzman G; Canpinar H; Kansu E
Hematol Oncol; 2004 Jun; 22(2):43-53. PubMed ID: 15386563
[TBL] [Abstract][Full Text] [Related]
58. Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias.
Samir Motawy M; Salfiti R; Khalifa F; Fayyaz S; Baker H
J Chemother; 1989 Apr; 1(2):123-7. PubMed ID: 2732780
[TBL] [Abstract][Full Text] [Related]
59. Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.
Alexander TB; Lacayo NJ; Choi JK; Ribeiro RC; Pui CH; Rubnitz JE
J Clin Oncol; 2016 Dec; 34(34):4094-4101. PubMed ID: 27507877
[TBL] [Abstract][Full Text] [Related]
60. Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia.
Thomas X; Cambier N; Taksin AL; Reman O; Vekhoff A; Pautas C; Leblond V; Soler-Michel P; Ecstein-Fraïssé E; Archimbaud E
Leuk Res; 2000 Nov; 24(11):957-63. PubMed ID: 11086179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
